News

Public · Published

TD Cowen maintains Encompass Health at Buy, raises price target to $150 from $140

TD Cowen kept its Buy rating on Encompass Health and raised its price target to $150 from $140, a 7.1% increase. That target implies 14.1% upside from the October 29 close of $131.49.

Published:

Updated:

What happened

TD Cowen kept its Buy rating on Encompass Health and raised its price target to $150 from $140, a 7.1% increase. That target implies 14.1% upside from the October 29 close of $131.49.

Confirmed

Global impact / market context

A higher price target shows this analyst expects the shares to be worth more, which can draw investor attention and buying interest to Encompass Health stock. Greater demand can lift the share price and the value of holdings.

Analyst inference

Other recent analyst notes carry targets of $150 or more, suggesting several analysts see room for the share price to rise. That can encourage investors to buy or hold Encompass Health shares rather than sell them.

Analyst inference

What to watch

  1. TD Cowen's $150 target sits within the recent range of $150 to $156 set by three analyst notes published in the past 30 days. Confirmed
  2. Watch whether other analysts change their ratings or price targets on Encompass Health, since such shifts can alter investor views and buying or selling of the stock. Proposed
  3. Watch the share price relative to the $131.49 close and the $150 target, because moving toward that level could change how investors judge the remaining upside. Analyst inference

Evidence

  • Original source link unavailable